LBRX trades 21.0% below Wall Street's consensus target of $39.50.
Last 12 months price action with 12-month analyst target path
The base valuation assumes LBRX achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, LB Pharmaceuticals Inc Common Stock (LBRX) has a Wall Street consensus price target of $39.50, based on estimates from 1 covering analysts. With the stock currently trading at $32.64, this represents a potential upside of +21.0%. The company has a market capitalization of $936M.
Analyst price targets range from a low of $36.00 to a high of $45.00, representing a 23% spread in expectations. The median target of $38.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, LBRX trades at a trailing P/E of -32.6x. Analysts expect EPS to grow -154.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
SAVACassava Sciences, Inc. | $64M | $1.32 | — | — | Buy | — | 12 |
ATHAAthira Pharma, Inc. | $17M | $4.34 | — | — | — | — | — |
INVAInnoviva, Inc. | $1.7B | $23.14 | $37.00 | +59.9% | Buy | 6.5x | 10 |
ACADACADIA Pharmaceuticals Inc. | $4.3B | $25.20 | $33.67 | +33.6% | Buy | 64.8x | 37 |
AXSMAxsome Therapeutics, Inc. | $12.4B | $241.12 | $262.38 | +8.8% | Buy | — | 26 |
INTRInter & Co, Inc. | $2.4B | $5.38 | $9.40 | +74.7% | Buy | 1.3x | 6 |
PRAXPraxis Precision Medicines, Inc. | $10.1B | $350.06 | $584.00 | +66.8% | Buy | — | 16 |
NRXPNRx Pharmaceuticals, Inc. | $69M | $4.00 | — | — | — | — | — |
CRLCharles River Laboratories International, Inc. | $10.9B | $225.57 | $214.14 | -5.1% | Buy | 20.3x | 37 |
IQVIQVIA Holdings Inc. | $32.8B | $193.28 | $219.44 | +13.5% | Buy | 15.1x | 44 |
Quick answers to the most common questions about buying LBRX stock.
The consensus Wall Street price target for LBRX is $39.5, representing 21.0% upside from the current price of $32.64. With 1 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
LBRX has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $39.5 implies 21.0% upside from current levels.
LBRX's current price is $32.64 with a consensus target of $39.5 (21.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $45 for LBRX, while the most conservative target is $36. The consensus of $39.5 represents the median expectation. These targets typically reflect 12-month expectations.
LBRX is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month LBRX stock forecast based on 1 Wall Street analysts shows a consensus price target of $39.5, with estimates ranging from $36 (bear case) to $45 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on LBRX, with a "Buy" consensus rating and $39.5 price target (21.0% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
LBRX analyst price targets range from $36 to $45, a 23% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $39.5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.